Urtoxazumab
Urtoxazumab
Urtoxazumab (pronounced: ur-tox-az-u-mab) is a monoclonal antibody designed for the treatment of Clostridium difficile infection (CDI). It is a type of biopharmaceutical that is still in the experimental stages of development.
Etymology
The name "Urtoxazumab" is derived from the International Nonproprietary Names (INN), where "Urtox" refers to the target, which is the toxin Urt produced by Clostridium difficile, "azu" is a stem used in INN to denote monoclonal antibodies, and "mab" is a common suffix for monoclonal antibodies.
Mechanism of Action
Urtoxazumab works by binding to the toxin Urt produced by Clostridium difficile, neutralizing its effects and preventing it from causing damage to the host cells. This mechanism of action is similar to other antitoxin monoclonal antibodies.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Clostridium difficile infection: A type of bacterial infection that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon.
- Biopharmaceutical: A type of drug produced using biotechnology.
- Antitoxin: A substance that acts against a specific toxin in the body.
External links
- Medical encyclopedia article on Urtoxazumab
- Wikipedia's article - Urtoxazumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski